ベータ
治験レーダーAI
治験 NCT05359991 (Project REACH)(対象:嚢胞性線維症、鎌状赤血球症、SARS-CoV-2感染症)は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。
フィルター基準に一致する試験が1件見つかりました
タイル表示

Exercise in Child Health (Project REACH)

募集中
治験(臨床試験)の詳細は主に英語で提供されています。しかし、治験レーダーAIが支援できます!「治験を説明」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT05359991 (Project REACH) は 介入研究 臨床試験 で、嚢胞性線維症、鎌状赤血球症、SARS-CoV-2感染症 に関するものです。現在は 募集中 で、2020年11月12日 から開始しています。240 名の参加者 の募集が計画されています。この治験は カリフォルニア大学アーバイン校 によって主催され、2026年1月1日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2025年7月10日 です。
概要
This study is a cooperative investigation funded by the NIH. The project is a collaboration among three major NIH Clinical Translational Science Awardees: 1) UCI (lead site with its affiliate CHOC), 2) Northwestern University (with its affiliate Lurie Children's Hospital), and 3) USC (with its affiliate Children's Hospital of Los Angeles).

There is an increasing number of children who, through medical advances, now survive diseases and conditions that were once fatal, but which remain chronic and debilitating. A major challenge to improve both the immediate and long term care and health of such children has been the gap in our understanding of how to assess the biological effects of exercise. Like otherwise healthy children, children with chronic diseases and disabilities want to be physically active. The challenge is to determine what constitutes safe and beneficial level of physical activity when the underlying disease or condition [e.g., cystic fibrosis (CF) or sickle cell disease (SCD)] imposes physiological constraints on exercise that are not present in otherwise healthy children. Current exercise testing protocols were based on studies of athletes and high performing healthy individuals and were designed to test limits of performance at very high-intensity, unphysiological, maximal effort. These approaches are not optimal for children and adolescents with disease and disability. This project (REACH-Revamping Exercise Assessment in Child Health) is designed to address this gap. Cohorts of children will be identified with two major genetic diseases (CF and SCD) and measure exercise responses annually as they progress from early puberty to mid or late puberty over a 3-4year period. In addition, in the light of the pandemic, a group of children will be added who were affected by SARS-CoV-2 and investigate their responses to exercise. SARS-CoV-2 has similar long-term symptoms than CF and SCD have. Novel approaches to assessing physiological responses to exercise using advanced data analytics will be examined in relation to metrics of habitual physical activity, circulating biomarkers of inflammation and growth, leukocyte gene expression, and the impact of the underlying CF, SCD or SARS-CoV-2 condition. The data from this study will help to develop a toolkit of innovative metrics for exercise testing that will be made available to the research and clinical community.

詳細説明
New, generalizable approaches are needed for measuring physical fitness and activity across a spectrum of pediatric health and disease.

Exercise in children and adolescents is not merely play but is an essential component of growth and development. Children are among the most spontaneously physically active human beings. It is not surprising that participation in PA (Physical Activity) is a major determinant of health across the lifespan and health-related quality of life in both healthy children and in children with chronic diseases. Despite this essential biologic role for PA, children have not been spared the relentless reduction in levels of PA that is creating a crisis in health care in our nation and throughout the world. Recognition of the enormous morbidity and cost of physical inactivity-related diseases, such as atherosclerosis, type 2 diabetes, and osteoporosis, has spurred new policy initiatives targeting preventive medicine early in life. The concept of pediatric origins of adult health and disease is gaining scientific merit, highlighting the need to transform existing notions of how to evaluate health in a growing child. A physically inactive (even normal weight) child may have no symptoms of disease, but evidence of deterioration in vascular health may already be present. As era of population health management and precision medicine are approaching, the notion of what it means to be a healthy child must change and include robust metrics of physical fitness.

Equally worrisome is that the deleterious health effects of physical inactivity and poor fitness are exacerbated in children with chronic disease and/or disabilities or with environmental-lifestyle conditions like obesity. Children with diseases or conditions previously associated with mortality during the first two decades of life (e.g., SCD, CF) are living longer due to remarkable advances in research and care, but are often unable to achieve levels of PA and fitness associated with health benefits in otherwise healthy children. Not surprisingly, the healthspan [the period of life free from serious chronic diseases and disability of children with chronic diseases is threatened not only by the underlying disease, but by the compounding effects of insufficient PA and sedentary behavior. Increasing PA and fitness is feasible, but has proven quite challenging to implement in a systematic manner. Once a pattern of physical inactivity and a sedentary lifestyle is established, a vicious cycle ensues, in which constraints on PA harm immediate health and contribute to lifelong health impairment ranging from cardiovascular and metabolic disease to osteoporosis. Exactly what constitutes ideal physical fitness in a child with a chronic condition remains unknown. Finding beneficial levels of PA in children with chronic disease or disability is challenging because the optimal range of exercise is much narrower than in a healthy child. Finally, as a result of the COVID-19 pandemic a sizable number of children are experiencing long-term effects such as fatigue, and will be included in our study. Similar to children with CF and SCD, studies of exercise and physical activity will provide insight into disease mechanisms and possible therapies.

公式タイトル

Revamping Exercise Assessments in Child Health (Project REACH)

疾患/病気
嚢胞性線維症鎌状赤血球症SARS-CoV-2感染症
刊行物
この臨床試験について発表された科学記事と研究論文:
その他の研究識別子
  • Project REACH
  • 20195402
NCT番号
開始日
2020-11-12
最終更新日
2025-07-10
終了予定日
2026-01
目標参加者数
240
試験の種類
介入研究
治験の相・段階
該当なし
状況
募集中
主目的
基礎研究
割付方法
非無作為化
介入モデル
並行割当
盲検化
なし(非盲検)
群(アーム)/介入
参加グループ/群介入/治療法
実薬対照薬Healthy Controls
Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in healthy controls. Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur: * The child will be in a fasted state. * An IV will be placed into the child's arm. * Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise.
運動
Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
実験的Children With Documented History of SARS CoV-2 Infection
Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with a documented history of SARS CoV-2 Infection. Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur: * The child will be in a fasted state. * An IV will be placed into the child's arm. * Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise.
運動
Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
実験的Children With Sickle Cell Disease (SCD)
Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with Children With Sickle Cell Disease (SCD). Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur: * The child will be in a fasted state. * An IV will be placed into the child's arm. * Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise.
運動
Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
実験的Children With Cystic Fibrosis (CF)
Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with Children With Cystic Fibrosis (CF). Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur: * The child will be in a fasted state. * An IV will be placed into the child's arm. * Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise.
運動
Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
主要評価項目
評価指標指標の説明時間枠
Gas Exchange Variables
oxygen uptake
8 Months
Whole Body Lean Mass
Measured by Dual X-Ray Densitometry
8 Months
Physical Activity
Measured by Actigraphy
8 Months
Biomarkers
IGF-1
8 Months
Gene Expression
Circulating leukocyte gene expression associated with exercise
8 Months
Gas Exchange Variables
V̇O2
8 Months
Gas Exchange Variables
Carbon dioxide output
8 Months
Gas Exchange Variables
V̇CO2
8 Months
Gas Exchange Variables
ventilation
8 Months
Gas Exchange Variables
V̇E
8 Months
Gas Exchange Variables
heart rate (HR)
8 Months
Fat Mass
Measured by Dual Energy X-Ray Absorptiometry
8 Months
% Body Fat
Measured by Dual X-Ray Densitometry
8 Months
Whole Body Bone Mineral Content
Measured by Dual X-Ray Densitometry
8 Months
Whole Body Bone Mineral Density
Measured by Dual X-Ray Densitometry
8 Months
Biomarkers
IL6
8 Months
Biomarkers
C-Reactive Protein
8 Months
Biomarkers
Glucose
8 Months
Biomarkers
insulin
8 Months
Biomarkers
lipid screen
8 Months
Biomarkers
lactate
8 Months
Biomarkers
CBC
8 Months
Gene Expression
Circulating Leukocyte Gene Expression Associated with Sickle Cell Anemia
8 Months
Gene Expression
Circulating Leukocyte Gene Expression Associated with Cystic Fibrosis
8 Months
副次評価項目
評価指標指標の説明時間枠
Behavioral responses to exercise
PROMIS Parent Fatigue Questionnaire
8 Months
Standardized assessments
TANNER Staging Questionnaire
8 Months
Behavioral responses to exercise
PROMIS Pediatric Fatigue Questionnaire
8 Months
Behavioral responses to exercise
Project REACH NHANES PAQ Adapted Questionnaire
8 Months
Behavioral responses to exercise
PEDSQL Fatigue Questionnaire
8 Months
Behavioral responses to exercise
Appendices Questionnaire
8 Months
Standardized assessments
Block Standardized FFQ
8 Months
適格基準

対象年齢
小児
試験の最低年齢
10 Years
対象性別
全て
健康なボランティアを受け入れる
はい

Sickle Cell Disease

  • Tanner 1-5, corresponding approximately to ages 10-17 y/o
  • SCD diagnosis including all relevant genotypes
  • Determined to be in relatively good health as a patient with SCD with no complications from SCD that would render participation the study unadvisable
  • No evidence of other disease or disability that would impair participation in PA
  • Physician permission to perform CPET
  • BMI within the average range for age and condition

Cystic Fibrosis

  • Confirmed diagnosis of CF based on either two CF-causing mutations and/or a sweat chloride concentration of > 60 mmol/l after a positive newborn screening test or on two separate occasions
  • Tanner 1-5 corresponding approximately to ages 10-17 y/o as documented by a licensed independent provider at screening, or by a validated self-assessment tool
  • Determined to be in relatively good health as a patient with CF with no complications from CF that would render participation the study unadvisable as determined by a physician. Examples include history of submassive or massive hemoptysis or moderate to severe pulmonary hypertension.
  • BMI in the average range for age and condition
  • No evidence of other disease or disability that would impair participation in PA

Comparison (Healthy control)

  • Tanner 1-5 corresponding approximately to ages 10-17 y/o
  • Determined to be in good health by pre-participation history and physical examination performed by primary care providers or PERC staff
  • BMI and PA participation (by history) in the average range for age
  • No evidence of disease or disability that would impair participation in PA

Comparison (SARS-CoV-2)

  • Tanner 1-5 corresponding approximately to ages 10-17 y/o
  • Documented SARS-CoV-2 infection
  • Capable of doing exercise as determined by primary care providers or PERC a medical officer

Sickle Cell Disease Treatment for substance or alcohol abuse

  • Requiring chronic monthly transfusions
  • Other conditions that preclude exercise such as neuromotor disease, heart disease, or any other condition that would prevent a child from participating in PA

Cystic Fibrosis Treatment for substance or alcohol abuse

  • Other conditions that preclude exercise (such as neuromotor disease, heart disease, or any other condition that would prevent a child from participating in PA)
  • FEV1 < 40% predicted based on Global Lung Index equations
  • Current infection with Burkholderia cenocepacia or Mycobacterium abscessus

Comparison (Healthy control) Treatment for substance or alcohol abuse or chronic medication use • Determination by PERC staff of unsuitability for exercise

Comparison (SARS-CoV-2) Treatment for substance or alcohol abuse or chronic medication use

• Determination by PERC staff of unsuitability for exercise

University of California, Irvine logoカリフォルニア大学アーバイン校158 件のアクティブな治験を探索
  • 🏥Children's Hospital of Orange County
  • 🏥Children's Hospital Los Angeles
  • 🏥Ann & Robert H Lurie Children's Hospital of Chicago
責任者
Dan Cooper, 研究責任者, Professor, University of California, Irvine
試験中央連絡先
連絡先: Peter Horvath, Ph.D., (714) 456-8248, [email protected]
1 1カ国の場所

California

University of California, Irvine, Irvine, California, 92697, United States
Shlomit Radom-Aizik, Ph.D., 連絡先, (949) 824-2584, [email protected]
Dan Cooper, M.D., 連絡先, (949) 824-1923, [email protected]
募集中